Protective effects of erythropoietin on tau phosphorylation induced by β-amyloid

Journal of Neuroscience Research

Volumn 86, Issue 13, 2008, Pages 3018-3027

  Sun, Zhi Kun ^a   Yang, Hong Qi ^a   Pan, Jing ^a   Zhen, Hong ^a   Wang, Zhi Quan ^a   Chen, Sheng Di ^a   Ding, Jian Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

amyloid peptide; Alzheimer's disease; Erythropoietin; Tau phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; ERYTHROPOIETIN; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NEUROBLASTOMA CELL; NEUROPATHOLOGY; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; ERYTHROPOIETIN; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 57049090468     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21745     Document Type: Article

References (81)

1. Alvarez A, Toro R, Caceres A, Maccioni RB. 1999. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 459:421-426.
2. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. 2002. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4:153-165.
3. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST. 1999. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 93:3757-3773.
4. Behl C, Davis JB, Lesley R, Schubert D. 1994. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827.
5. Brettschneider J, Widl K, Ehrenreich H, Riepe M, Tumani H. 2006. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neurosci Lett 404:347-351.
6. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, Octave JN, Pradier L, Touchet N, Tremp G. 2001. Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 67:81-88.
7. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Grasso G, Corica F, Frisina N. 2002. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci 103:275-282.
8. Busciglio J, Lorenzo A, Yeh J, Yankner BA. 1995. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14:879-888.
9. Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, Akterin S, Pei JJ, Winblad B, Cowburn RF. 2003. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J Neurochem 87:1152-1164.
10. Chong ZZ, Li F, Maiese K. 2005a. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2:387-399.
11. Chong ZZ, Li F, Maiese K. 2005b. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 49:1-21.
12. Chung YH, Kim SI, Joo KM, Kim YS, Lee WB, Yun KW, Cha CI. 2004. Age-related changes in erythropoietin immunoreactivity in the cerebral cortex and hippocampus of rats. Brain Res 1018:141-146.
13. Damen JE, Krystal G. 1996. Early events in erythropoietin-induced signaling. Exp Hematol 24:1455-1459.
14. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G. 1995. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 14:5557-5568.
15. Diem R, Sattler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bahr M. 2005. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128:375-385.
16. Digicaylioglu M, Lipton SA. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647.
17. D'Ursi AM, Armenante MR, Guerrini R, Salvadori S, Sorrentino G, Picone D. 2004. Solution structure of amyloid beta-peptide 25-35 in different media. J Med Chem 47:4231-4238.
18. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, Siren AL. 2004a. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 19:195-206.
19. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, Woldt H, Falkai P, Knerlich F, Jacob S, von Ahsen N, Maier W, Bruck W, Ruther E, Cerami A, Becker W, Siren AL. 2004b. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 9:42-54.
20. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, Siren AL, Paulus W, Nave KA, Gold R, Bartels C. 2007. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130:2577-2588.
21. Ekinci FJ, Shea TB. 1999. Free PKC catalytic subunits (PKM) phosphorylate tau via a pathway distinct from that utilized by intact PKC. Brain Res 850:207-216.
22. Elyaman W, Terro F, Wong NS, Hugon J. 2002a. In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation. Eur J Neurosci 15:651-660.
23. Elyaman W, Yardin C, Hugon J. 2002b. Involvement of glycogen synthase kinase-3beta and tau phosphorylation in neuronal Golgi disassembly. J Neurochem 81:870-880.
24. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Gotz J. 2003. Beta-amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278:40162-40168.
25. Genc K, Genc S, Baskin H, Semin I. 2006. Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res Acad Sci Bohemoslovaca 55:33-38.
26. Giunta S, Galeazzi R, Valli MB, Corder EH, Galeazzi L. 2004. Transferrin neutralization of amyloid beta 25-35 cytotoxicity. Clin Chim Acta 350:129-136.
27. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. 1992. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147:58-62.
28. Hellstrom-Lindahl E. 2000. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 393:255-263.
29. Ishizawa T, Sahara N, Ishiguro K, Kersh J, McGowan E, Lewis J, Hutton M, Dickson DW, Yen SH. 2003. Co-localization of glycogen synthase kinase-3 with neuro.brillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 163:1057-1067.
30. Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS. 1995. The toxicity in vitro of beta-amyloid protein. Biochem J 311:1-16.
31. Iwatsubo T. 2000. [Alzheimer's disease: basic aspects]. Nippon Ronen Igakkai Zasshi 37:207-211.
32. Jamsa A, Hasslund K, Cowburn RF, Backstrom A, Vasange M. 2004. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. Biochem Biophys Res Commun 319:993-1000.
33. Joneja B, Wojchowski DM. 1997. Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain. J Biol Chem 272:11176-11184.
34. Juul SE, Anderson DK, Li Y, Christensen RD. 1998. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 43:40-49.
35. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. 1993. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609:29-35.
36. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. 1999. Effects of erythropoietin on neuronal activity. J Neurochem 72:2565-2572.
37. Kosuge Y, Sakikubo T, Ishige K, Ito Y. 2006. Comparative study of endoplasmic reticulum stress-induced neuronal death in rat cultured hippocampal and cerebellar granule neurons. Neurochem Int 49:285-293.
38. Kubo T, Nishimura S, Oda T. 2002. Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Brain Res 106:94-100.
39. Lasne F, de Ceaurriz J. 2000. Recombinant erythropoietin in urine. Nature 405:635.
40. Lee SM, Nguyen TH, Park MH, Kim KS, Cho KJ, Moon DC, Kim HY, Yoon DY, Hong JT. 2004. EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun 320:1087-1095.
41. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. 2004. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242.
42. Lewczuk P, Hasselblatt M, Kamrowski-Kruck H, Heyer A, Unzicker C, Siren AL, Ehrenreich H. 2000. Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport 11:3485-3488.
43. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS. 2004. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88:554-563.
44. Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR. 2004. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 6:659-671; discussion 673-681.
45. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, et al. 1994. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4:1077-1086.
46. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, Mandelkow E. 1992. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 314:315-321.
47. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, Reina M, Vilaro S, Fabre M. 2003. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 18:2538-2544.
48. 25-35 peptide and examination of underlying mechanisms. Neurochem Int 46:575-583.
49. Miura O, D'Andrea A, Kabat D, Ihle JN. 1991. Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol 11:4895-4902.
50. Mori H, Ihara Y. 1991. Neuro.brillary tangles, dystrophic neurites (curly fibers), and abnormal phosphorylation of tau. Brain Pathol 1:273-277.
51. Mulot SF, Hughes K, Woodgett JR, Anderton BH, Hanger DP. 1995. Phosphorylation of tau by glycogen synthase kinase-3 beta in vitro produces species with similar electrophoretic and immunogenic properties to PHF-tau from Alzheimer's disease brain. Biochem Soc Trans 23:45S.
52. + hematopoietic progenitor cells. Exp Hematol 30:990-1000.
53. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. 1995. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64:253-265.
54. Pregi N, Vittori D, Perez G, Leiros CP, Nesse A. 2006. Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells. Biochim Biophys Acta 1763:238-246.
55. Remy I, Wilson IA, Michnick SW. 1999. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990-993.
56. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. 2002. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 277:9684-9689.
57. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J, Dirnagl U, Meisel A. 2002. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22:10291-10301.
58. Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B. 2003. Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312:922-929.
59. Ryder J, Su Y, Ni B. 2004. Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell Signalling 16:187-200.
60. Sakamoto H, Kitamura T, Yoshimura A. 2000. Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells. J Biol Chem 275:35857-35862.
61. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. 1998. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635-4640.
62. Sinor AD, Greenberg DA. 2000. Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity. Neurosci Lett 290:213-215.
63. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. 2001a. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98:4044-4049.
64. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. 2001b. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 101:271-276.
65. Siren AL, Radyushkin K, Boretius S, Kammer D, Riechers CC, Natt O, Sargin D, Watanabe T, Sperling S, Michaelis T, Price J, Meyer B, Frahm J, Ehrenreich H. 2006. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain 129:480-489.
66. Sui X, Krantz SB, You M, Zhao Z. 1998. Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 92:1142-1149.
67. Sui X, Krantz SB, Zhao ZJ. 2000. Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br J Haematol 110:63-70.
68. Sun Y, Jin K, Childs JT, Xie L, Mao XO, Greenberg DA. 2006. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. Dev Biol 289:329-335.
69. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. 1993. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 90:7789-7793.
70. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K. 1996. Exposure of rat hippocampal neurons to amyloid beta peptide 25-35 induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosc Lett 203:33-36.
71. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H. 1998. Activation of tau protein kinase I/ glycogen synthase kinase-3beta by amyloid beta peptide 25-35 enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31:317-323.
72. von Lindern M, Parren-van Amelsvoort M, van Dijk T, Deiner E, van den Akker E, van Emst-de Vries S, Willems P, Beug H, Lowenberg B. 2000. Protein kinase C alpha controls erythropoietin receptor signaling. J Biol Chem 275:34719-34727.
73. Wang Y, Kilic E, Kilic U, Weber B, Bassetti CL, Marti HH, Hermann DM. 2005. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128:52-63.
74. Wang YP, Wang XC, Tian Q, Yang Y, Zhang Q, Zhang JY, Zhang YC, Wang ZF, Wang Q, Li H, Wang JZ. 2006. Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells. J Neural Transm 113:1723-1732.
75. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, Wang Q, Xu H, Wang JZ. 2006. Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 98:1167-1175.
76. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. 1999. Signal transduction in the erythropoietin receptor system. Exp Cell Res 253:143-156.
77. Yang HQ, Ba MW, Ren RJ, Zhang YH, Ma JF, Pan J, Lu GQ, Chen SD. 2007. Mitogen activated protein kinase and protein kinase C activation mediate promotion of sAPPalpha secretion by deprenyl. Neurochem Int 50:74-82.
78. Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250:279-282.
79. Zhande R, Karsan A. 2007. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol 292:H2467-H2474.
80. Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. 2002. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115:201-211.
81. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. 2002. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11:270-281.